The most effective way to tackle debilitating diseases is to punch them at the start and keep them from growing. Research shows that a small “molecular tweezer” keeps proteins from clumping, the first step of disorders such as Parkinson’s disease, Alzheimer’s disease and Huntington’s disease.
If you follow cancer biology, then you’ve probably heard of ubiquitin before. In a recent paper researchers provided a structural rationale for how ubiquitin helps RIG-I do its job— and how that might help keep the immune system from getting out of hand.
A team of scientists published details of how a class of drugs called “HDACis” drive muscle-cell regeneration in the early stages of dystrophic muscles, but fail to work in late stages. The findings are key to furthering clinical development of HDACis for Duchenne muscular dystrophy (DMD), an incurable muscle-wasting disease.
A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The drug companies said Tuesday they will "vigorously challenge" the decision. The U.S District Court in western Louisiana ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly.
A research team was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. Tau deposits, along with beta-amyloid plaques, are among the characteristic features of Alzheimer's disease.
The U.S. Food and Drug Administration has approved the first tablet for gradually reducing hay fever allergy symptoms, an alternative to uncomfortable allergy-desensitizing shots. Oralair, a tablet that dissolves quickly under the tongue, is approved for patients aged 10 through 65. It's to be...
Researchers from the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, in collaboration with materials scientists, engineers and neurobiologists, have discovered a new mechanism for using light to activate drug-delivering nanoparticles and other targeted therapeutic substances inside the body.
It doesn’t take long for the flu virus to outsmart Tamiflu. EPFL scientists have developed a tool that reveals the mutations that make the virus resistant, and they have identified new mutations that may render ineffective one of the few treatments currently available on the market.
New guidelines that ease the recommended blood pressure could result in 5.8 million U.S. adults no longer needing hypertension medication. The findings are the first peer-reviewed analysis to quantify the impact of guidelines announced in February by the Eighth Joint National Committee. In a divisive move, the committee relaxed the blood pressure goal in adults 60 years and older to 150/90, instead of the previous goal of 140/90.
Women who are pregnant or trying to become pregnant and taking a folic acid supplement may be at risk of reducing their folate benefit through sun exposure, a new QUT study has warned. A study of 45 young healthy women in Brisbane aged 18 to 47, showed high rates of sun exposure accounted up to a 20 per cent reduction in folate levels.
Scientists of the KIT and the University of Kiev have produced an antibiotic, whose biological activity can be controlled with light. Thanks to the robust diarylethene photoswitch, the antimicrobial effect of the peptide mimetic can be applied in a spatially and temporally specific manner. This might open up new options for the treatment of local infections, as side effects are reduced.
Scientists in Göttingen have solved the high-resolution structure of the molecular transporter TSPO, which introduces cholesterol into mitochondria. This protein also serves as a docking site for diagnostic markers and different drugs, such as Valium. The detailed knowledge of its three-dimensional shape and function opens up new diagnostic and therapeutic perspectives.
Almost half of Americans ages 40 to 75 and nearly all men over 60 qualify to consider cholesterol-lowering statin drugs under new heart disease prevention guidelines, an analysis concludes. It's the first independent look at the impact of the guidelines issued in November and shows how dramatically they shift more people toward treatment.
Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018. However, a major bottleneck has prevented peptide drugs from reaching their full potential: Manufacturing the peptides takes several weeks.
It won't be nearly as much fun as eating candy bars, but a big study is being launched to see if pills containing the nutrients in dark chocolate can help prevent heart attacks and strokes.
As long as inexpensive statins, which lower cholesterol, are readily available and patients don’t mind taking them, it doesn’t make sense to do a heart scan to measure how much plaque has built up in a patient’s coronary arteries before prescribing the pills, according to a new study.
Using technologies and computational modeling that trace the destiny of single cells, researchers at the University of California, San Diego School of Medicine describe for the first time the earliest stages of fate determination among white blood cells called T lymphocytes, providing new insights that may help drug developers create more effective, longer-lasting vaccines against microbial pathogens or cancer.
A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check – for more than two years, in some cases – in many patients with advanced melanoma, according to a new study. The study provides the longest-term look so far at how melanoma patients have fared since receiving the drug, nivolumab, in a Phase 1 clinical trial.
The bark of the Amur cork tree (Phellodendron amurense) has traveled a centuries-long road with the healing arts. Now it is being put through its paces by science in the fight against pancreatic cancer, with the potential to make inroads against several more.
A team of researchers identified mutations in a gene that can reduce the risk of developing type 2 diabetes, even in people who have risk factors such as obesity and old age. The results focus the search for developing novel therapeutic strategies for type 2 diabetes; if a drug can be developed that mimics the protective effect of these mutations, it could open up new ways of preventing this devastating disease.
A team of scientists from UCLA's Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.
Acetaminophen provides many people with relief from headaches and sore muscles. When used appropriately, it is considered mostly harmless. Over recent decades, the drug has become the medication most commonly used by pregnant women for fevers and pain. Now, a long-term study by UCLA, in collaboration with the University of Aarhus in Denmark, has raised concerns about the use of acetaminophen during pregnancy.
A new bioprinting method creates intricately patterned 3D tissue constructs with multiple types of cells and tiny blood vessels. The work represents a major step toward a longstanding goal of tissue engineers: creating human tissue constructs realistic enough to test drug safety and effectiveness.
The development of drugs to treat acute stroke or aid in stroke recovery is an endeavor that only rarely pays off in the form of approval. Drug companies spend years testing safety and dosage in the clinic, only to find in Phase 3 clinical efficacy trials have little to no benefit. A robot developed at MIT may help speed up drug development, letting companies know earlier in the process whether a drug will work in stroke patients.
The drugmaker working to develop a pill to boost sexual desire in women says regulators are demanding more studies on the experimental drug. Sprout Pharmaceuticals said that the Food and Drug Administration wants to see more data on how the company's drug, flibanserin, interacts with other medications and how it affects driving ability. Nearly 10 percent of women studied in company trials reported sleepiness while taking the daily pill.